Hormonal changes in females are shifts in the levels of key chemical messengers, primarily estrogen, progesterone, and several brain-signaling hormones, that occur throughout a woman’s life. These changes drive puberty, regulate the monthly menstrual cycle, sustain pregnancy, and eventually lead to menopause. Understanding what happens at each stage can help you recognize what’s normal, what’s not, and what your body is actually doing behind the scenes.
Puberty: Where It All Starts
Puberty typically begins between ages 8 and 13 in girls. The process kicks off in the brain, where a region called the hypothalamus starts releasing a hormone called GnRH in pulses. Before puberty, this signal is kept quiet. About a year before any visible changes, the brain lifts that suppression, and GnRH begins stimulating the pituitary gland to release two other hormones: FSH (follicle-stimulating hormone) and LH (luteinizing hormone).
The very first measurable sign that puberty is approaching is the appearance of pulsatile LH release during sleep. FSH and LH then signal the ovaries to start producing estrogen, which triggers breast development, body fat redistribution, growth spurts, and eventually the first menstrual period. This entire hormonal cascade unfolds over several years, not overnight, which is why puberty feels gradual even though the underlying shifts begin well before physical changes are visible.
The Monthly Menstrual Cycle
Once menstruation begins, hormone levels follow a predictable monthly rhythm divided into two main phases. The average cycle lasts about 28 days, though anything from 21 to 35 days is considered normal.
Follicular Phase
The first half of the cycle, from the start of your period to ovulation, is driven by rising estrogen. FSH stimulates follicles in the ovary to grow, and as they develop, they produce increasing amounts of estradiol (the most active form of estrogen). Early in this phase, estradiol production is relatively low, around 36 micrograms per day. By the time ovulation approaches, it surges more than tenfold to about 380 micrograms per day. Progesterone stays minimal during this stretch, around 1 milligram daily.
Ovulation
The estrogen surge triggers a spike in LH from the pituitary gland, which causes the dominant follicle to release an egg. Estradiol actually drops sharply just before the LH peak, partly because rising progesterone begins to suppress estrogen production. This brief hormonal crossover is what makes the fertile window so narrow, typically lasting only about 24 to 48 hours.
Luteal Phase
After the egg is released, the empty follicle transforms into a structure that pumps out progesterone. Daily progesterone production jumps from about 4 milligrams at ovulation to roughly 25 milligrams at mid-luteal phase. Estradiol rises again to about 250 micrograms per day during this period. Progesterone thickens the uterine lining and makes cervical mucus thick and opaque, creating a less hospitable environment for sperm. If no pregnancy occurs, both hormones drop at the end of the cycle, the uterine lining sheds, and the cycle starts over.
Pregnancy Hormones
When a fertilized egg implants, the hormonal landscape changes dramatically. The body begins producing hCG (human chorionic gonadotropin), the hormone detected by pregnancy tests. At the time of a missed period, hCG levels are around 100 IU/L. They then climb rapidly, peaking at roughly 100,000 IU/L between weeks 8 and 10 of pregnancy before settling at a lower plateau for the remainder.
hCG’s early job is to keep the ovary producing progesterone, about 25 milligrams per day, until the placenta takes over production around weeks 10 to 12. By the end of pregnancy, progesterone levels reach 100 to 200 nanograms per milliliter, with the placenta producing approximately 250 milligrams daily. Estrogen also climbs steadily throughout pregnancy, reaching levels far higher than at any other point in a woman’s life.
After delivery, both estrogen and progesterone plummet within hours. This rapid withdrawal is one of the factors linked to postpartum mood changes, since estrogen plays a direct role in regulating brain chemistry tied to mood (more on that below).
Perimenopause and Menopause
Perimenopause, the transition leading up to menopause, usually starts in a woman’s 40s but can begin in the mid-30s. Rather than a smooth decline, estrogen levels become volatile during this stage, swinging unpredictably high and low from one cycle to the next. Periods may become irregular, closer together, or further apart. This hormonal instability is what drives hot flashes, night sweats, sleep disruption, and mood shifts.
Menopause itself is defined as 12 consecutive months without a period. For healthy women over 45 experiencing symptoms like hot flashes and irregular cycles, no blood test is needed for diagnosis. For women between 40 and 45 with symptoms, an FSH level above 30 IU/L helps confirm the transition. After menopause, the ovaries produce very little estrogen, and progesterone production essentially stops.
Effects on Bone and Heart Health
Estrogen slows the natural breakdown of bone tissue. When estrogen drops after menopause, bone loss accelerates significantly. Up to 20% of bone density can be lost during the menopausal transition and the years immediately following it. One in two postmenopausal women will develop osteoporosis, and most of those women will experience a fracture during their lifetime. These fractures, particularly of the hip and spine, are associated with chronic pain, reduced mobility, and increased risk of death.
The cardiovascular protective effects of estrogen also diminish after menopause, which is one reason heart disease risk rises in women after this transition.
How Hormones Affect Mood
Estrogen directly influences the brain’s production and regulation of serotonin and dopamine, two chemical messengers central to mood, motivation, and emotional stability. Estrogen boosts the activity of the enzyme that produces serotonin and modifies how serotonin receptors function, effectively increasing serotonin signaling in the brain. It also affects dopamine production through multiple pathways, helping maintain steady levels of this reward and motivation chemical.
This connection explains why mood disturbances tend to cluster around times of hormonal flux: the days before a period (when estrogen and progesterone drop), the postpartum period (when both plummet), and perimenopause (when estrogen swings erratically). The issue isn’t simply “low” estrogen. It’s the rate and unpredictability of change that the brain struggles to adapt to.
Stress and Reproductive Hormones
Chronic stress raises cortisol, the body’s primary stress hormone, which can directly disrupt the reproductive hormone chain. Elevated cortisol suppresses the pulsatile release of GnRH from the hypothalamus, the same signal that initiates the entire cascade of FSH, LH, estrogen, and progesterone. When this signal is dampened, ovulation can be delayed or skipped entirely, leading to irregular or missed periods. Stress also raises prolactin levels, which further impairs cycle regularity and can reduce the chances of conception.
This is why significant life stress, intense exercise, or eating disorders can cause periods to stop. It’s not a coincidence or a minor inconvenience. It reflects genuine suppression of the reproductive hormone axis by the stress response system.
Polycystic Ovary Syndrome (PCOS)
PCOS is the most common hormonal disorder in women of reproductive age, characterized by an excess of androgens (hormones like testosterone that are typically higher in males). Diagnosis requires at least two of three features: irregular or absent ovulation, signs of excess androgens (such as acne, excess hair growth, or elevated blood levels), and a high number of small follicles on the ovaries, currently defined as 25 or more follicles per ovary on ultrasound.
The follicle threshold has evolved over the years. It was originally set at 12 follicles in 2003, but improvements in ultrasound technology revealed that many healthy women meet that number. A 2014 meta-analysis found that the median follicle count in women of reproductive age is between 13 and 16, so the threshold was raised to 25 or more to avoid overdiagnosis. A normal follicle count is now considered 4 to 24 per ovary. PCOS disrupts the normal hormonal cycle by producing too many androgens, which interfere with follicle maturation and prevent regular ovulation.
Thyroid Hormones in Women
Although not a reproductive hormone, thyroid function has a significant relationship with female hormonal health. The normal TSH range is roughly 0.4 to 4.5 mU/L for most adults, with the median falling between 1.0 and 1.5 mU/L. In women over 70, the upper limit extends to about 6.0 mU/L, reflecting a natural age-related shift rather than disease.
Pregnancy alters thyroid function directly. In the first trimester, rising hCG stimulates the thyroid, often pushing free T4 higher and TSH lower. By the third trimester, free T4 levels typically fall to the lower end of the normal range or slightly below it. This is why thyroid screening during pregnancy uses trimester-specific reference ranges rather than standard ones. Unrecognized thyroid dysfunction during pregnancy can affect both fertility and fetal development.
Hormone Therapy for Menopause
Menopausal hormone therapy provides the most benefit when started during perimenopause or within 10 years of menopause, ideally before age 60. For women who experience menopause before age 40 (known as primary ovarian insufficiency) or before 45, hormone therapy is recommended regardless of whether symptoms are present, because the long-term health risks of prolonged estrogen deficiency, including osteoporosis and cardiovascular disease, outweigh the risks of treatment.
There is no fixed time limit for how long hormone therapy should continue. As long as the lowest effective dose is used and regular follow-up is maintained, routine discontinuation at age 60 or 65 is not considered necessary. For women over 65, periodic attempts to taper are advised. The therapy is not appropriate for women with a history of breast cancer, active blood clots, unexplained vaginal bleeding, or significant liver disease. The risk of blood clots is highest in the first year of treatment, and patches or gels applied to the skin carry a lower clot risk than oral forms.